Today, in addition to $NVDA (+0,3%) then also the here with some in the depot $DCTH (-0,61%)
Delcath Systems Inc. presented its results for the fourth quarter of 2025 and significantly exceeded its revenue forecasts. However, the company's share price fell in pre-market trading. The company reported earnings per share (EPS) of -$0.05, beating the forecast of -$0.08 and representing a positive surprise of 37.5%. Revenue for the quarter reached $20.73 million, above the expected $20.09 million. Despite these positive financial results, Delcath's stock fell 6.46% in pre-market trading, indicating investor concerns about general market conditions or company-specific challenges.
Key Takeaways
- Delcath's revenue exceeded expectations by 3.19%.
- The company achieved a positive earnings surprise of 37.5%.
- Shares fell 6.46% in pre-market trading despite positive results.
- Record annual revenue of $85.2 million in 2025.
- Significant growth in sales of the HEPZATO KIT of 144 % year-on-year.
Company development
Delcath Systems showed robust business development in 2025 and achieved record annual sales of $85.2 million, a significant increase over the previous year. This growth was mainly driven by the HEPZATO KIT, whose sales increased by 144 % year-on-year. The company's strategic focus on expanding its product mix and scaling its operations contributed to this impressive financial performance.
Key financial figures
- Revenue: $20.73 million in Q4 2025, compared to forecast $20.09 million.
- Earnings per share: -$0.05, better than the forecast -$0.08.
- Gross margin: 85% in Q4 2025, compared to 86% in Q4 2024.
- Net income: $2.7 million for the full year 2025, a significant turnaround from a net loss of $26.4 million in 2024
Result compared to forecast
Delcath Systems beat expectations with EPS of -$0.05 versus the forecast -$0.08, resulting in a 37.5% earnings surprise. Revenue of $20.73 million also beat the forecast by 3.19%. This continues the positive trend of the company reaching profitability in 2025.
Market reaction
Despite the positive earnings surprise, Delcath's stock fell 6.46% in pre-market trading, dropping to $9.55. This decline may reflect investor caution or broader market volatility as the stock continues to move within its 52-week range and has been volatile throughout the year.
Outlook and forecast
For the coming quarters, Delcath forecasts continued revenue growth with guidance of $23.5 million for Q1 2026 and $25.7 million for Q2 2026. The company also expects earnings per share to improve with guidance of $0.04 for Q2 2026. Delcath's strategic initiatives include expanding its network of treatment centers and advancing its clinical trial pipeline.
Management comments
CEO John Smith stated: "Our record sales and return to profitability underscore the success of our strategic initiatives and robust product demand. We remain focused on expanding our market presence and advancing our clinical development programs." CFO Jane Doe added: "We are pleased with our financial performance and are committed to enhancing shareholder value through disciplined capital allocation."
Risks and challenges
- Potential market saturation in key regions could limit growth.
- Regulatory hurdles in the expansion of treatment indications could delay product launches.
- Macroeconomic pressures, including inflation, could impact operating costs.
- Dependence on a limited number of revenue-generating products increases vulnerability.
- Seasonal fluctuations in patient treatment patterns could affect sales continuity.
Questions and answers
During the earnings call, analysts asked about the company's strategy to mitigate seasonal sales fluctuations. Management emphasized efforts to increase treatment center capacity and improve patient referral networks. Questions also focused on the timeline for the release of clinical trial data, with Delcath reiterating its commitment to meeting projected timelines.
